Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY | Market Cap | 5.30T -26.4% |
| Revenue (ttm) | 2.05T +14.3% |
| Net Income | 304.60B +23.9% |
| EPS | 163.74 +27.1% |
| Shares Out | 1.85B |
| PE Ratio | 17.51 |
| Forward PE | 13.55 |
| Dividend | 78.00 (2.72%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 7,237,900 |
| Average Volume | 8,081,115 |
| Open | 2,771.00 |
| Previous Close | 2,867.00 |
| Day's Range | 2,763.50 - 2,884.00 |
| 52-Week Range | 2,684.00 - 4,178.00 |
| Beta | -0.30 |
| RSI | 39.38 |
| Earnings Date | Apr 24, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ... [Read more]
Financial Performance
In fiscal year 2025, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.
Financial StatementsNews
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
HAMBURG, Germany & MUNICH--(BUSINESS WIRE)--GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology
JONESBORO, Ark.--(BUSINESS WIRE)--SylamoreBio, a biotechnology company pioneering advanced therapeutic delivery to the central nervous system (CNS) and other recalcitrant tissues, today announced it h...
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effectiv...
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). T...
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma...
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen ...
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines TORONTO, Jan. 21, 2026 /PRNewswire/ - Daiichi Sankyo (TSE: 4568) has further...
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe.
US FDA approves Daiichi Sankyo's therapy to treat breast cancer
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea , Dec. 15, 202...
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstr...
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern Di...
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
- The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity medicines,...
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. D...
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations...
Daiichi Sankyo Establishes Third Research Institute in San Diego
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside o...
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics
MADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Immuto Scientific Announces Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfa...
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different dose...
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and diff...
Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 Worl...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...